Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim versus placebo in adults with persistent or chronic primary immune thrombocytopenia
ChiCTR-IPR-15007011Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Placebo Group with Romiplostim for injection Group (2 arms). Primary endpoint: Number of weeks with platelet response during comparative period. Started Jun 2015; status: recruiting.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR-IPR-15007011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007011.